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Screening for Hepatitis C Virus Infection in Adolescents and Adults
US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force
Summary of Recommendation
Importance
Hepatitis C virus (HCV) is the most common chronic blood-
borne pathogen in the US and a leading cause of complica-
tions from chronic liver disease.1 Hepatitis C virus infection is asso-
ciated with more deaths than the top 60 other reportable
infectious diseases combined, including HIV.2 The most important
risk factor for HCV infection is past or current injection drug use.1
In the US, an estimated 4.1 million persons have past or current
HCV infection (ie, they test positive for the anti-HCV antibody).
Of these persons who test positive for the anti-HCV antibody,
approximately 2.4 million have current infections based
on testing with molecular assays for HCV RNA.1,3-5 The esti-
mated prevalence of chronic HCV infection is approximately 1.0%
(2013 to 2016).6 An estimated 44 700 new HCV infections
occurred in the US in 2017.7 Cases of acute HCV infection have
increased approximately 3.8-fold (2010 to 2017) over the last
decade because of increasing injection drug use and improved
surveillance.7 The most rapid increase in acute HCV incidence has
been in young adults aged 20 to 39 years who inject drugs, with
increases in both sexes but more pronounced in men.7 Rates
increased especially in American Indian/Alaskan Native and non-
Hispanic white populations.7
Assessment of Magnitude of Net Benefit
The US Preventive Services Task Force (USPSTF) concludes with
moderate certainty that screening for HCV infection in adults aged
18 to 79 years has substantial net benefit.
See the Figure and Table for more information on the USPSTF
recommendation rationale and assessment. For more details on
the methods the USPSTF uses to determine net benefit, see the
USPSTF Procedure Manual.8
Practice Considerations
Patient Population Under Consideration
This recommendation applies to all asymptomatic adults aged 18 to
79 years without known liver disease.
IMPORTANCE Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in
the US and a leading cause of complications from chronic liver disease. HCV is associated with
more deaths than the top 60 other reportable infectious diseases combined, including HIV.
Cases of acute HCV infection have increased approximately 3.8-fold over the last decade
because of increasing injection drug use and improved surveillance.
OBJECTIVE To update its 2013 recommendation, the USPSTF commissioned a review of the
evidence on screening for HCV infection in adolescents and adults.
POPULATION This recommendation applies to all asymptomatic adults aged 18 to 79 years
without known liver disease.
EVIDENCE ASSESSMENT The USPSTF concludes with moderate certainty that screening for
HCV infection in adults aged 18 to 79 years has substantial net benefit.
RECOMMENDATION The USPSTF recommends screening for HCV infection in adults aged 18 to
79 years. (B recommendation)
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Assessment of Risk
Although all adults aged 18 to 79 years should be screened, a num-
ber of risk factors increase risk. The most important risk factor for
HCV infection is past or current injection drug use. In the US, recent
increases in HCV incidence have predominantly been among young
persons who inject drugs (PWID).1,9 Approximately one-third of
PWID aged 18 to 30 years are infected with HCV, and 70% to 90%
of older PWID are infected.9 Clinicians may want to consider screen-
ing in adolescents younger than 18 years and in adults older than 79
years who are at high risk (eg, past or current injection drug use).
Pregnant adults should be screened. HCV prevalence has
doubled in women aged 15 to 44 years from 2006 to 2014.1,10,11
From 2011 to 2014, 0.73% of pregnant women tested had an HCV
infection, with a 68% increase in the proportion of infants born to
HCV-infected mothers.1,10 Approximately 1700 infected infants
are born annually to 29 000 HCV-infected mothers.1,11 Because
of the increasing prevalence of HCV in women aged 15 to 44 years
and in infants born to HCV-infected mothers, clinicians may want
to consider screening pregnant persons younger than 18 years.
Screening Tests
Screening with anti-HCV antibody testing followed by polymerase
chain reaction testing for HCV RNA is accurate for identifying pa-
tients with chronic HCV infection.9 Currently, diagnostic evalua-
tions are often performed with various noninvasive tests that have
lower risk for harm than liver biopsy for diagnosing fibrosis stage or
cirrhosis in persons who screen positive.12
Among patients with abnormal results on liver function tests
(measurement of aspartate aminotransferase, alanine aminotrans-
ferase, or bilirubin levels) who were tested for reasons other than
HCV screening, finding the cause of the abnormality often includes
testing for HCV infection and is considered case finding rather than
screening; therefore, it is outside the scope of this recommendation.
Screening Intervals
Most adults need to be screened only once. Persons with contin-
ued risk for HCV infection (eg, PWID) should be screened periodi-
cally. There is limited information about the specific screening in-
terval that should occur in persons who continue to be at risk for new
HCV infection or how pregnancy changes the need for additional
screening.
Screening Implementation
Important considerations for implementation of screening include
(1) communicating to patients that screening is voluntary and un-
dertaken only with the patient’s knowledge and understanding that
Figure. Clinical Summary: Screening for Hepatitis C Virus Infection in Adolescents and Adults
What does the USPSTF
recommend?
For adults aged 18 to 79 years: Grade B
To whom does this
recommendation apply?
What’s new?
How to implement this
recommendation?
The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize
decision-making to the specific patient or situation.
All asymptomatic adults (including pregnant persons) aged 18 to 79 years without known liver disease.
This recommendation expands the population that should be screened. The USPSTF now recommends that all adults aged 18
to 79 years be screened. Previously, it recommended screening adults born between 1945 and 1965 and others at high risk.
How often?
One-time screening for most adults. 
Periodically screen persons with continued risk for HCV infection (eg, persons with past or current injection drug use). 
There is limited evidence to determine how often to screen persons at increased risk. 
What are other 
relevant USPSTF 
recommendations?
The USPSTF has made recommendations on screening for hepatitis B virus infection in pregnant persons, hepatitis B virus
infection in adults, and HIV infection. These recommendations are available at https://www.uspreventiveservicestaskforce.org.
Screen. Screen adults aged 18 to 79 years with anti–HCV antibody testing followed by confirmatory polymerase chain
reaction testing.
a. The USPSTF also suggests that clinicians consider screening persons younger than 18 years and older than 79 years who
are at high risk for infection (eg, those with past or current injection drug use).
Adults with a positive screening test result are usually followed up with a diagnostic evaluation using one of various
noninvasive tests. Treatment typically consists of oral direct-acting antiviral regimens for 8 to 12 weeks.
Important considerations include
• Communicating that screening is voluntary and undertaken only with the patient's knowledge
• Informing patients about HCV infection, how it can (and cannot) be acquired, the meaning of positive and negative test
results, and the benefits and harms of treatment
• Providing patients the opportunity to ask questions and to decline screening
Where to read the full
recommendation
statement?
Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the
recommendation, including benefits and harms; supporting evidence; and recommendations of others.
Screen adults for hepatitis C virus (HCV) infection.
March 2020
USPSTF indicates US Preventive Services Task Force.
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HCV screening is planned; (2) informing patients about HCV infec-
tion, how it can (and cannot) be acquired, the meaning of positive
and negative test results, and the benefits and harms of treatment;
and (3) providing patients the opportunity to ask questions and to
decline screening.
Some health care systems serving insured populations, some
academic medical centers, and the Veterans Health Administration
have achieved high rates of HCV screening and treatment. How-
ever, national HCV screening rates in community health centers and
from the National Health Interview Study were 8.3% and 17.3%, re-
spectively; 1 study of 4 safety-net primary care practices serving low-
income and uninsured or underserved populations found that only
0.8% of persons born in 1945 through 1965 were screened over a
1-year period.13 Implementation of successful screening may re-
quire addressing various barriers to screening and treatment in di-
verse populations, such as the uninsured.
Treatment
The purpose of antiviral treatment regimens for HCV infection
is to prevent long-term health complications of chronic HCV infec-
tion (eg, cirrhosis, liver failure, and hepatocellular carcinoma).
Currently, all oral direct-acting antiviral (DAA) regimens with-
out interferon have been accepted as the standard treatment for
chronic HCV infection. Antiviral therapy is not generally consid-
ered during pregnancy because of the lack of data on the safety of
newer DAA regimens during pregnancy and breastfeeding.14,15
Additional Tools and Resources
The Centers for Disease Control and Prevention provides strate-
gies for implementing a testing program and additional risk factors
at https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm.16
Other Related USPSTF Recommendations
The USPSTF has made recommendations on screening for hepati-
tis B virus infection in pregnant persons,17 screening for hepatitis B
virus infection in adults,18 and screening for HIV infection.19
Update of Previous USPSTF Recommendation
This recommendation incorporates new evidence and replaces the
2013 USPSTF recommendation, which recommended screening for
HCV infection in persons at high risk for infection and 1-time screen-
ing in adults born between 1945 and 1965 (B recommendation).20
The new USPSTF recommendation expands the ages for screening
to all adults from 18 to 79 years.
The treatment of HCV continues to evolve, resulting in greater
benefits and fewer harms than when the USPSTF last considered the
evidence. Direct-acting antiviral regimens are of shorter duration,
with higher rates of sustained virologic response (SVR) and fewer
serious harms than previous treatment regimens. Since 2013, the
prevalence of HCV infection has increased in younger persons aged
20 to 39 years. There are limited epidemiologic data available on HCV
incidence in adolescents younger than 18 years. The HCV infection
prevalence rates in older adults born between 1945 and 1965 re-
main relatively high, and prevalence in the elderly will increase as
this population ages. Clinical trials of DAA treatment included adults
in their early 80s, which increases the evidence for the benefits of
screening in older adults. In addition, many older adults could ex-
perience the benefits of screening. As a result, the USPSTF con-
cluded that broadening the age for HCV screening beyond its pre-
vious recommendation will identify infected patients at earlier stages




The USPSTF commissioned a systematic evidence review to up-
date its prior review (from 2013) on screening for HCV infection.20,21
The scope of this review is similar to that of the prior systematic re-
view, except in the current review, the USPSTF also examined the
Table. Summary of USPSTF Rationale for Screening for Hepatitis C Virus Infectiona
Rationale Assessment
Detection • There is adequate evidence that HCV testing (screening for the anti-HCV antibody followed by confirmation of active
infection by HCV RNA assay for persons who test positive) accurately detects HCV infection
• There is adequate evidence for 1-time testing in all adults and periodic testing in persons at continued risk
of new HCV infection
• There is inadequate evidence on the timing of repeat testing
Benefits of early detection and
treatment (based on direct or
indirect evidence)
• There is no direct evidence on the benefit of screening for HCV infection on health outcomes in asymptomatic adults.
There is inadequate direct evidence on the effect of treatment on health outcomes in adults and adolescents. However,
there is convincing evidence that the newer DAA regimens result in SVR in a very high proportion (>95%) of adults aged
18 to 79 y and adequate evidence of SVR in adolescents.
• There is adequate evidence of a consistent association between SVR after antiviral therapy and improved health outcomes
(decreased risk of all-cause mortality, mortality due to liver disease, cirrhosis, and hepatocellular carcinoma)
• Given the accuracy of the screening test and the availability of effective interventions for HCV infection, the USPSTF
determined that the indirect evidence is adequate that the magnitude of the benefit of screening and treatment is
substantial for adults aged 18 to 79 y
Harms of early detection and
treatment
• Potential harms of screening include anxiety, patient labeling, and feelings of stigmatization. There is inadequate direct
evidence on the harms of screening for HCV infection.
• Currently recommended DAA regimens are associated with fewer harms than older interferon-containing therapies,
and treatment duration is shorter at 8 to 12 weeks. There is adequate evidence that DAA regimens are associated
with low rates of serious adverse effects and withdrawal due to adverse effects.
• There is adequate evidence to bound the overall harms of screening and treatment as small based on the known harms
of treatment, the high accuracy of screening, and the low likelihood of harms from a blood draw
USPSTF assessment • The USPSTF concludes with moderate certainty that screening for HCV infection in adults aged 18 to 79 y has substantial
net benefit
Abbreviations: DAA, direct-acting antiviral; HCV, hepatitis C virus; SVR, sustained
virologic response; USPSTF, US Preventive Services Task Force.
a See the eFigure in the Supplement for explanation of USPSTF grades and
levels of evidence.
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evidence on adolescents.21 For treatment, the USPSTF focused on
currently recommended DAA regimens.
Accuracy of Screening Tests and Risk Assessment
The USPSTF previously found HCV screening to be highly accurate.20
The USPSTF found no new evidence on the yield of repeat vs 1-time
screening or alternative screening strategies (eg, different risk- or
prevalence-based methods).
Benefits of Early Detection or Treatment
The USPSTF found no direct evidence on the benefits of HCV screen-
ing vs no screening on health outcomes or the effects of prenatal
HCV screening on the risk of vertical transmission.1 Treatment stud-
ies focused on populations without cirrhosis who are more likely to
be asymptomatic and identified by screening. Of the trials of DAA
regimens (n = 7167; 26% to 69% female; mean age, 45 to 62 years),
14 were multinational; 11 were conducted in the US or Canada; and
the remainder were conducted in New Zealand, Egypt, France, or
Asia. In 29 trials, 60% to 100% of patients were white.1 The trials
evaluated a variety of DAA regimens recommended in current guide-
lines. Treatment duration was 12 weeks in all but 2 trials, which al-
located patients to either 8 or 12 weeks of treatment. Eleven trials
were of good quality and 22 were of fair quality. Forty-nine trials
found DAA regimens to be associated with pooled SVR rates rang-
ing from 95.5% to 98.9% across genotypes. Evidence was greatest
for genotype 1 infection (32 trials), the most frequent genotype in
the US.1 Sustained virologic response rates were similar in trials that
stratified patients according to age, sex, race/ethnicity, or treat-
ment experience with non-DAA regimens.1
Direct evidence on the effects of current DAA regimens on
health outcomes is limited.1 Pooled analysis from 10 trials found
small, short-term improvements in quality of life scale scores after
treatment with a DAA regimen compared with baseline scores.1
Trials reporting short-term mortality (<1 year) found few events and
were not designed to detect differences in mortality rates. Twenty-
one trials reported no deaths; in the other 10 trials, there were 17
deaths (0.4% [17/3848] overall).1
The USPSTF review evaluated the linkage between achieving
SVR after antiviral therapy vs no SVR and health outcomes. Sus-
tained virologic response after antiviral therapy was consistently as-
sociated with decreased risk of all-cause mortality (13 studies; pooled
hazard ratio [HR], 0.40 [95% CI, 0.28-0.56]), liver mortality (4 stud-
ies; pooled HR, 0.11 [95% CI, 0.04-0.27]), cirrhosis (4 cohorts in 3
studies; pooled HR, 0.36 [95% CI, 0.33-0.40]), and hepatocellular
carcinoma (20 studies; pooled HR, 0.29 [95% CI, 0.23-0.38]) vs no
SVR, after adjustment for potential confounders.1
The USPSTF found limited new evidence on the risk of vertical
transmission. Five observational studies found no clear association
between risk of vertical transmission of HCV infection and the mode
of delivery.21 One good-quality US study showed that prolonged rup-
ture of membranes (>6 hours) was associated with increased risk of
HCV transmission in 189 mother-infant pairs compared with mem-
brane rupture lasting less than 6 hours (adjusted odds ratio, 9.3 [95%
CI, 1.5-180]).1,22 One observational study in 188 mother-infant pairs
found that internal fetal monitoring was associated with an in-
creased risk of vertical transmission of HCV infection compared with
external monitoring (adjusted odds ratio, 6.7 [95% CI, 1.1-35.9]).1,22
Three observational studies did not find a clear association be-
tween breastfeeding and an increased risk of vertical transmission
of HCV infection.1
The evidence is also limited in adolescents. Seven trials (n = 300)
reported SVR rates in adolescents taking DAA regimens similar to
those taken by adults (97%-100%).1 However, some of the trials
evaluated regimens that are not approved by the US Food and Drug
Administration for use in adolescents.1 Direct-acting antiviral
regimens recommended and approved by the US Food and Drug
Administration for use in adolescents are ledipasvir/sofosbuvir,
sofosbuvir/ribavirin, and glecaprevir/pibrentasvir.1 The evidence on
antiviral treatment and health outcomes in adolescents is very lim-
ited. One post hoc before-and-after analysis found that scores based
on the Pediatric Quality of Life Inventory (ie, school and social func-
tioning) improved from baseline to 24 weeks after treatment with
a DAA regimen.1
Modeling studies that compared screening in all persons 18 years
and older with birth cohort screening suggested that expanded
screening strategies would be beneficial, despite different assump-
tions regarding chronic HCV infection progression and rates of link-
age to care.1 One analysis of a hypothetical cohort of the US popu-
lation used more conservative assumptions and found that screening
everyone 18 years and older would identify an estimated 256 000
additional HCV cases and lead to an estimated 280 000 additional
individuals who achieve SVR and an estimated 4400 fewer cases
of hepatocellular carcinoma over a lifetime.1,23
Harms of Screening or Treatment
The USPSTF did not identify any new studies providing direct evi-
dence on screening harms. Poor-quality evidence from the prior re-
view suggested potential negative psychological and social effects
from HCV screening.1,24
Direct-acting antiviral regimens are associated with fewer harms
than older interferon-containing therapies. Treatment duration has
shortened from 24 to 48 weeks with older interferon-containing regi-
mens to 8 to 12 weeks.1 In DAA trials (33 trials; n = 7167) with ad-
verse event data, the pooled rate of any adverse event was 73.3%.1
Rates of serious adverse events (1.9%) and withdrawal due to ad-
verse events (0.4%) were low compared with rates reported for in-
terferon-containing regimens.1 Pooled rates of specific adverse
events ranged from 2.4% for anemia to 18.4% for headache and were
also lower when compared with rates reported for older interferon-
containing therapies.1 The most common adverse events were fa-
tigue, headache, nausea, and diarrhea.1
Seven nonrandomized, open-label trials (n = 300) in adoles-
cents examined treatment harms. Five trials reported no withdraw-
als due to adverse events; 1 trial reported a serious adverse event
(grade 3 joint injury). The rate of any adverse event was 27% in 1 trial
and 71% to 84% in 4 trials. Specific adverse event rates across trials
ranged from 3% to 48% for headache (7 trials), 5% to 53% for fa-
tigue (7 trials), and 3% to 28% for gastrointestinal adverse events
(nausea, vomiting, or diarrhea) (5 trials).1 Three trials reported no
deaths in adolescents (n = 182) treated with DAA regimens.1 These
trials were not designed to evaluate long-term harms associated with
DAA treatment during adolescence.1
Response to Public Comment
A draft version of this recommendation statement was posted
for public comment on the USPSTF website from August 27 to
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September 23, 2019. Some comments asked for a definition of
“high risk”; however, an extensive list of risk factors is beyond the
scope of this recommendation statement. The Additional Tools and
Resources section provides a link to other resources. Some com-
ments expressed concern about the lack of guidance on screening
intervals for pregnant adults. In response, the USPSTF added lan-
guage to the Practice Considerations section. Some comments raised
concerns about implementation. In response, the USPSTF added
language about counseling and consent to the Screening Implemen-
tation section. Some comments urged more research on the ben-
efits and harms of treatment in pregnant adults. The USPSTF clari-
fied its call for research in pregnant persons in the Research Needs
and Gaps section.
Research Needs and Gaps
Addressing several key research gaps could help inform the benefit
of screening for HCV infection in US-based populations:
• Research is needed on the yield of repeat vs 1-time screening for
HCV and different repeat screening intervals to inform recommen-
dations on optimal screening intervals for persons at high risk.
• Research is needed to identify labor management practices
(eg, prolonged rupture of membranes or use of internal fetal moni-
toring) and treatment of HCV infection prior to pregnancy to re-
duce the risk of mother-to-child transmission. Research is also
needed on the benefits and harms of additional screening during
pregnancy for low-risk persons who have been previously screened.
• Trials and cohort studies that measure effects on quality of life, func-
tion, and extrahepatic effects of HCV infection (eg, renal func-
tion, cardiovascular effects, or diabetes) would be helpful for evalu-
ating the effects of DAA regimens on short-term health outcomes.
• Additional studies are needed to examine the epidemiology of HCV
infection and the effectiveness of DAA regimens in adolescents.
Recommendations of Others
The Centers for Disease Control and Prevention is in the process of
updating its HCV screening guidelines. Its draft screening guideline
recommends screening for HCV at least once in a lifetime for all adults
18 years and older, except in settings where the prevalence is less
than 0.1%. All pregnant persons should be screened for HCV dur-
ing each pregnancy, except in settings where the prevalence of HCV
infection is less than 0.1%. All persons with risk factors (eg, persons
with HIV, prior recipients of blood transfusions, persons who ever
injected drugs and shared needles, and persons who are born to an
HCV-infected mother) should be tested for HCV, with periodic test-
ing while risk factors persist.25 The American College of Obstetri-
cians and Gynecologists recommends offering HCV screening to
pregnant persons with risk factors.26 The American Association for
the Study of Liver Diseases and the Infectious Diseases Society of
America recommends 1-time routine, opt-out HCV screening for all
persons 18 years and older and 1-time testing for all persons younger
than 18 years at increased risk of HCV exposure. They also recom-
mend periodic testing for persons with an increased risk of HCV ex-
posure and annual HCV testing for all PWID and for HIV-infected men
who have unprotected sex with men.27
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